Stay updated with breaking news from David Urech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion
J&J will pick up Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab Therapeutics, for $1.25 billion to acquire all assets related to NM26.
NM26-2198 is a first-in-class bi-specific antibody designed to simultaneously block multiple targets for the treatment of moderate to severe atopic dermatitis (AD) Combined single ascending dose
Numab Therapeutics AG ("Numab") and Ono Pharmaceutical Co., Ltd. ("Ono") today announced that Ono has exercised its option to enter into a development and license agreement for a multispecific antibody